ALIGNSIGHT MEDICAL / 視準醫智

Aligning AI with clinical expertise.

We are developing an expert-centered platform for abnormal blood cell morphology review, with the goal of making each review consistent, inspectable and traceable.

OUR PURPOSE

Build around the people who make the final judgment.

Blood morphology connects image interpretation with professional experience. AlignSight Medical brings those strengths together through an AI-assisted workflow that professionals can inspect, correct and review over time.

Our long-term vision is a blood morphology quality-management platform that can support validated workflows across institutions and imaging systems.

PROGRESS & MILESTONES

From a working prototype to the next stage.

2026

Working research prototype

The current research prototype connects image analysis, 16-category morphology pre-classification, expert correction and review records. Its categories include mature and immature cell types, labels suggestive of abnormal morphology, and artifacts.

View the prototype demo
September 2026

2026 NTU Precision Medicine Demo Day Finalist

AlignSight Medical was named a finalist in the 2026 NTU Precision Medicine Demo Day startup competition.

Official finalist list
Current evidence

Image-level evaluation

A fixed held-out test evaluates the 16-category morphology classifier on 3,212 cell images. Clinical workflow and external validation are the next priorities.

Evaluation results & scope

OUR TEAM

Clinical insight meets engineering.

Our team spans medical laboratory science, electrical and computer engineering, and intelligent healthcare. Work is organized around clinical needs, AI and data, software development, and commercialization.

I-Sin Chiu (Anita)

I-Sin Chiu (Anita)

CEO / Certified Medical Laboratory Scientist (Taiwan)

Ben Fang

Ben Fang

CTO

Hank Chui

Hank Chui

Business Development Lead

Ryan Liu

Ryan Liu

AI Expert

David Lin

David Lin

AI Expert

Vincent Huang

Vincent Huang

Certified Medical Laboratory Scientist (Taiwan)

01

Medical laboratory science

Clinical workflow, morphology review and validation design.

02

Electrical & computer engineering

Image analysis, AI models, software and data systems.

03

Intelligent healthcare

Connecting product design with clinical use and quality management.

MARKET & BUSINESS

Validate in Taiwan. Build for a broader opportunity.

Medical laboratory scientists and hematopathology teams are the intended users. Hospitals, health systems and clinical laboratories are the intended customers, with a planned B2B annual platform license and implementation, integration and support services.

Our first priority is to validate workflow value and adoption requirements with clinical partners in Taiwan. U.S. market exploration focuses on hospital hematology laboratories and reference laboratories with digital imaging capacity and a need for consistent, traceable morphology review.

DEVELOPMENT ROADMAP

A staged path from prototype to platform.

Next 12 months · goals

Clinical validation

Seek 2–3 clinical validation sites and 1–2 proof-of-concept collaborations. Define the study protocol, assess usability and review outcomes, and clarify the regulatory pathway.

Stage 02

Integration & external evidence

Develop imaging and LIS/HIS interfaces, multi-site validation and formal product governance.

Stage 03

Multi-site deployment

Build repeatable deployment and support processes, then evaluate international partnerships.

These are development goals, subject to evidence, partner requirements and regulatory review. Pilot sites and proof-of-concept collaborations are targets, not completed partnerships.

COLLABORATION

Build the next stage with us.

We are seeking clinical and industry partners to validate YMCA and develop its path to deployment.

Clinical validation partners

Hematology laboratories and morphology experts for authorized, de-identified images, expert annotations, usability studies and workflow comparisons.

Imaging & integration partners

Microscope-camera and scanner partners, LIS/HIS integrators and security specialists for compatibility testing and hospital deployment planning.

Product & commercialization partners

Medtech investors, regulatory and quality advisors, and international partners to support validation, product development and market access.

r14945044@ntu.edu.tw